Onconase

Onconase

Experimental oncology
A ribonuclease derived from the oocytes of the frog Rana pipiens, which was in clinical trials for treating mesothelioma.
 
Adverse effects
Anorexia, flushing, vertigo.

Onconase®

P30 Protein Oncology A ribonuclease-like protein derived from frog–Rana pipiens–embryos, said to be effective against some CAs–eg, mesothelioma. See Unproven methods for cancer management.
References in periodicals archive ?
A form of the drug, formerly known by the ONCONASE trademark and as "Onconase for injection", was previously evaluated by the US Food and Drug Administration for over twenty years in numerous clinical trials.
and Alfacell Corporation have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE (ranpirnase) from Alfacell.
GENESIS Pharma Announce Licensing Agreement for ONCONASE in Southeast Europe(C)2006 JeraOne - http://www.
It is important to realize that Onconase, our lead compound, has been in clinical studies for other oncology indications and has proven itself to be well tolerated in over 1,000 patients treated to date.
The fusion protein consists of ONCONASE (ranpirnase) and a humanized anti-CD22 monoclonal antibody.
Moreover, Onconase, our lead candidate, has been in clinical studies for other indications and has proven to be well tolerated in over 1,000 patients treated to date.
Alfacell Corporation (Bloomfield, NJ; 973-748-8082), a leader in the research and development of ribonuclease enzymes with anti-cancer and other therapeutic proper-ties, announced the company has been issued new European Patent 837 878 that covers the amino acid sequence, method of manufacture, and a natural variant of its proprietary drug ONCONASE.
If granted, orphan drug status will entitle ONCONASE to seven years of marketing exclusivity for the UMM indication after FDA approval.
ONCONASE, the first of a new class of novel cancer drugs from Alfacell's innovative ribonuclease (RNase) technology platform, clearly meets this standard.
Krauss's work involves the creation of novel immunomodular forms suitable for specifically targeting ONCONASE to tumors.
Considering Onconase's overall safety profile, its ability to overcome MDR, I believe that Onconase remains a viable candidate for second line therapy in MM.
Shogen will continue as CEO, and will focus on the continued development of ONCONASE and Alfacell's other novel ribonuclease product candidates, including those from its cadre of amphinases, for other indications, as well as advancing the company's promising research in the microRNA, siRNA, and RNAi areas.